Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.46 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922594 | 0.89 | TDP1 (0.41) | P2RY1FPR2SCN9ATDP1CFTR | |
| SCHEMBL11991497 | 0.88 | P2RY1 (0.43) | P2RY1FPR2SCN9ATDP1ROCK2 | |
| SCHEMBL11922572 | 0.84 | FPR2 (0.48) | P2RY1FPR2SCN9ATDP1MAPT | |
| SCHEMBL11922625 | 0.84 | P2RY1 (0.43) | P2RY1TDP1CFTRPTK2SSTR4 | |
| SCHEMBL13044770 | 0.83 | CFTR (0.53) | P2RY1FPR2SCN9ATDP1ROCK2 | |
| SCHEMBL11922610 | 0.81 | SCN9A (0.34) | SCN9ACFTRMAPTPTK2 | |
| SCHEMBL12303350 | 0.80 | P2RY1 (0.49) | P2RY1ROCK2MAPTCARM1PRMT6 | |
| SCHEMBL11922586 | 0.80 | FPR2 (0.41) | P2RY1FPR2SCN9A | |
| SCHEMBL11922595 | 0.79 | PTK2 (0.34) | SCN9ACFTRMAPTPTK2 | |
| SCHEMBL11922560 | 0.77 | ESRRA (0.37) | CFTRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| WO-2009018657-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | P2RY1 1687/4885FPR2 2994/4885SCN9A 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.